Bladder cancer displays an aggressive phenotype in the muscle-invasive phase, and is associated with a high mortality rate. Therefore, novel molecular therapeutic targets are needed to improve patient survival. A monoclonal antibody against the extracellular domain of the claudin-4 (CLDN4) tight junction protein was established by immunizing rats with a plasmid vector encoding human CLDN4. A hybridoma clone, producing a rat monoclonal antibody recognizing CLDN4 (clone 4D3). was obtained. Immunohistochemistry by using the 403 antibody showed that CLON4 expression was associated with local invasion, nodal metastasis, distant metastasis, and advanced stage in 86 cases of bladder cancer. The 403 antibody inhibited growth, invasion, and survival, associated with abrogation of the intratumoral microenvironment; lowered concentrations of epidermal growth factor and vascular endothelial growth factor were found in three-dimensional cultures ofT24 and RT4 cells. In combination with cisplatin therapy, 403 enhanced cisplatin cytotoxicity by increasing cellular permeability, leading to increased intracellular cisplatin concentrations. In mouse models of subcutaneous tumors and lung metastasis, 403 enhanced tumor growth inhibition, alone and with concurrent cisplatin treatment. The anti-tumor activity of the newly established 403 antibody suggests that it may be a powerful tool in CLDN4-targeting therapy, and in combination with chemotherapy.
Introduction
Bladder cancer was estimated to account for 15,000 deaths in the USA in 2013 [1] . and accounted for 7299 deaths in japan in 2012 [2] . Approximately 80% of newly diagnosed bladder cancers are nonmuscle-invasive urothelial tumors, which are treated with transurethral resection. Tumor recurrence and progression to invasive disease occurs in 70% and 15% oftreated cases, respectively [3] . In contrast, muscle-invasive urothelial cancers (MIUC) display more aggressive behavior, with a 50% mortality rate from disseminated disease [4] . Radical cystectomy is the gold-standard treatment Abbreviations: MIUC, muscle invasive urothelial cancers; CLDN, claudin; SPR, surface plasmon resonance; CDDP, cisplatinum; EGFR. epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; EGF, epidermal growth factor; VEGF, vascular endothelial growth factor; ADCC, antibody-dependent cellular cytotoxicity; CPE, Clostridium perfringens enterotoxin; C-CPE, (-terminal domain of CPE; ICG, indocyanin green; FITC, fluorescein isothiocyanate.
• Corresponding author. Tel.: +81 744 22 3051; fax : +81 744 25 7308. £-mail address: cooninh@zb4.so-net.ne.jp (H. Kuniyasu). [11] [12] [13] [14] [15] [16] . CLDN4 expression is associated with malignant phenotypes, including metastasis, in cancer cells [9,17,1 8 ] . Ovarian cancer cells expressing CLDN4 show increased invasion, motility, and survival [1 9], and CLDN4 overexpression has been observed in advanced ovarian cancer [ 12] . CLDN4 expression has also been associated with a more invasive phenotype in pancreatic intraductal papillary mucinous neoplasms [16] . CLDN4 is thought to be a relevant molecular marker for diagnosis and treatment of epithelial cancers [ 17, 18] , and also a promising therapeutic target for drug development [20, 21] . In the present study, we established a monoclonal antibody (mAb) specific to the extracellular domain of CLDN4, to target CLDN4-expressing cells. The antitumor characteristics of the mAb were examined in bladder cancer models.
Materials and methods

Cells and reagents
T24 and RT4 human bladder cancer cell lines were purchased from the American Type Culture Collection (ATCC; Manassas. VA. USA). Human CLDN (hCLDN)-expressing HT1080 cells were cultured in Dulbecco"s modified Eagle's medium (DMEM). supplemented with 10% fetal bovine serum (FBS). Mouse CLDN (mCLDN)-expressing L cells, kindly provided by Dr. S. Tsukita (Kyoto University, Japan), were cultured in modified Eagle's medium (MEM) containing 10% FBS.
Cell growth and apoptosis
Cell growth was assessed using a tetrazolium (MTT) dye assay, as previously described [22 ) . Apoptosis was assessed by examination of 2000 cells, stained with Hoechst 33342 dye (Life Technologies, Carlsbad, CA, USA), using a fluorescent microscope.
Chamber invasion assay
A modified Hoyden chamber assay was performed to examine the in vitro invasion of colon cancer cells [23) . Following incubation at 37 oc for 24 hours, the filters were carefully removed from the inserts, stained with hematoxylin for 1 0 min. and mounted on microscopic slides. The number of stained cells in each insert was counted at 100x magnification. Invasion activity was quantified by calculating the average number of cells per insert well. These experiments were performed in triplicate.
Reagents
CM5 sensor chips, amine-coupling reagents (N-ethyi-N0-[3-dimethylaminopropyl)-carbodiimide [EDC), N-hydroxysuccinimide [NHS), and ethanolamine-HCI), and HBS-EP + (10 mM HEPES, pH 7.4, 150 mM NaCI, 3 mM EDTA, and 0.05% surfactant P20) were obtained from GE Healthcare (Buckinghamshire, UK). Osplatin (CDDP) was purchased from Novaplus (Bedford, OH, USA). All reagents used were of research grade.
Animals
Four-week-old BALB/c Slc-nufnu mice and BALB/cCrSic mouse were purchased from SLC Japan (Shizuoka, Japan). The mice were maintained according to the institutional guidelines approved by the Committee for Animal Experimentation of Nara Medical University, in accordance with the current regulations and standards of the Ministry of Health, Labor, and We lfare. Their sex and age were designated at each experimental method.
Production of anti-human CLDN4 monoclonal antibody
Wister rats were immunized with a eukaryotic expression vector encoding the full-length hCLDN4 cDNA, and the production of anti-hCLDN4 mAb in the serum was assessed by using fluorescence-activated cell sorter (FACS) analysis using hCDLN4-expressing HT1 080 cells. B cells were isolated from rats with an increased serum titer of anti-hCLDN4 antibody, and the cells were fused with mye loma cells (P3U1 ), resulting in the production of hybridoma cells. Anti-hCLDN4 mAb-producing hybridoma cells were selected by using FACS, by their ability to bind to transient hCLDN4-expressing 293T cells and not to unexpressing 293T cells, using fluoresceinIabeled goat anti-rat IgG (H + L) (Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA) as a secondary antibody, resulting in the isolation of a rat anti-hCLDN4 mAb (clone 4D3). The immunoglobulin class was determined using a rat immunoglobulin isotyping enzyme-linked immunosorbent assay (ELISA) kit (BD Biosciences, San Jose, CA, USA).
Preparation of hCLDN4 proteins
Recombinant hCLDN4 protein was prepared by using Sf9 cells infected with recombinant baculovirus, as previously reported [24) . Briefly, the (-terminal histagge d hCLDN4 cDNA fragment was cloned into pFastBac1 , and recombinant baculovirus was generated by using a Bac-to-Bac baculovirus expression system (Life Technologies). Sf9 cells were infected with the recombinant baculovirus. After 52-56 h of infection, the cells were ha1vested by centrifugation. The cells were washed with phosphate-buffered saline {PBS) and resuspended in 10 mM Hepes buffer (pH 7.4, 120 mM NaCI ) with protease inhibitor tablets (Complete Mini, EDTA-free) (Roche Applied Science, lndianapolis, IN, USA), 1 mM phenylmethylsulfonyl fluoride, and 20 unitsfmL DNase I. The cells were lysed by the addition of 2% n-dodecyl-b-Dmaltoside (DDM) and subsequently centrifuged. The resultant supernatant was applied to HisTrapTM HP (GE Healthcare), and hCLDN4 was eluted using imidazole. The solvent containing hCLDN4 was exchanged for PBS containing 0.2% DDM. by gel filtration with a HiTrap Desalting column (GE Healthcare). Purification of CLDN4 was confirmed by sodium dodecyl sulfate polyacrylamide gel-electrophoresis (SDS-PAGE), followed by staining with Coomassie brilliant blue (CBB).
Swface plasmon resonance analysis
Surface plasmon resonance (SPR) measurements were performed using a Biacore T200 instrument (GE healthcare). Amine-coupl ing chemistry was used to immobilize anti-rat mAb on a CM5 sensor chip surface in a Biacore TM200, and equilibrated w ith HBS-EP+. The carboxymethyl surface of the CM5 chip was activated with a 1:1 ratio of 0.4 M EDC a nd 0.1 M NHS. Anti-rat mAb was diluted to 20 11g/mL in 10 mM acetate (pH 4.5) and applied to the chip surface. Excess activated groups were blocked by using 1 M ethanolamine (pH 8.5 ). Approximately 5000 RU of anti-rat mAb were immobilized. The culture supernatant of 4D3-producing hybridoma cells was then applied to the chip surface for 2 min. hCLDN4 protein was serially diluted (10, 100, 200, 300 and 500 nM) in HBS-EP+. Within a single binding cycle, hCLDN4 protein was applied sequentially, in order of increasing concentration, over both the ligand and the reference surfaces. The reference surface, an unmodified flowcell, was used to correct for systematic noise and instrumental drift. The sensorgrams were globally fitted by using a 1:1 binding model to determine association rate (ka), dissociation rate (kd), and equilibrium dissociation constant (KD) values, using Biacore T200 Evaluation Software (GE Healthcare).
Pwijication of rat anti-human CLDN4 monoclonal antibody
Eight-week-old female BALB/c Slc-nufnu mice (SLC) were intraperitoneally administered with pristane as an immunological adjuvant, and 1 x 10 7 4D3-producing hybridoma cells. Ascites was collected, and the m Ab ( 4D3) was purified by using Ab-Capcher ExTra (ProteNova, Kagawa, japan). Eluted mAb was dialyzed into PBS, and the protein concentration was determined by measuring absorbance at 280 nm. The purity of the mAb was confirmed by SDS-PAGE, followed by staining with CBB.
CLDN specificity analysis
To analyze specific binding of 403 to CLDN-expressing cells, hCLDN-expressing HT1080 cells and mCLDN4-expressing L cells were detached and incubated with S11g/ mL of 4D3, followed by treatme nt with secondary fluorescein-conjugated goat antirat lgG (H + L) (Kirkegaard and Peny Laborat01ies). The mAb-bound cells were analyzed by using FACSCalibur and CeiiQuestPro software (BD Biosciences).
Patients
Eighty-six cases of bladder cancer that had been treated with t ransurethral resection or total cystectomy in Nara Medical University Hospital w ere randomly selected. Basic patient information is summarized in Table 1 . As written informed consent was not obtained, any identifying information was removed from the samples prior to analysis, to ensure strict privacy protection (unlinkable anonymization). All procedures were performed in accordance w ith the Ethical Guidelines for Human Genome/Gene Research enacted by the Japanese Government, which was approved by the Ethics Committee of Nara Medical University (Approval Number 937).
Immunohistochemistry
Consecutive 4-llm sections were immunohistochemically stained using the immunoperoxidase technique described previously [25) . 403 was used at a concentration of 0.2 11g/mL Secondary antibodies (Medical and Biological Laboratories, Nagoya,japan) were used at a concentration of0.2 ).lg/mL Tissue sections we re calordeveloped with diamine benz idine hydrochloride (DAKO, Glastrup, Denmark), and counterstained with Meyer's hematoxylin (Sigma Chemical Co .. St. Louis, MO, USA). We count the cells with the immunoreaction at the cytoplasmic membrane. Staining strength was scored from 0 to 3 (a score of1 was used to describe the expression level in nonnal urothelium ). The staining index was calculated as the staining strength score multiplied by the staining area {%), and the resulting scores were defined as follows: none (index, 0), weak (index, 1-100), medium (index, 1 01 -200), and high (i ndex. 201-300). For a negative control, unimmunized rat lgG (Santa-Cm z Biotechnology, Santa-Cruz. CA, USA) was used as primary antibody.
Reverse transcription-polymerase chain reaction
Reverse transcription-polymerase chain reaction (RT-PCR). using 0.5 J.Lg total RNA extracted using an RN easy kit (Qiagen, Germanytown, MD, USA ), was used to assess human CLDN4 mRNA expression. The primer sets for human CLDN4 amplification were as follows: forward 5'-CfC CAT GGG GCf ACA GGT M-3' and reverse 5'-AGC AGC GAG TCG TAC ACC TT-3' (NCBI Reference Sequence: NM_001305.4; synthesized by Sigma Genosys. lshikari. japan). PCR products were electrophoresed in a 2% agarose gel and stained with ethidium bromide. ,8-actin (ACTB) mRNA was also amplified for use as an internal control (GenBank Accession No. NM_001101).
Quantitative reverse transcription-polymerase chain reaction
Extraction of total RNA was carried out using an RNeasy Mini Kit (Qiagen). and total RNA ( 1 J.Lg) was synthesized using the ReverTra Ace-a-RT Kit (Toyobo. Osaka, japan). Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was pe rformed by using StepOne Real-Time PCR System with Fast SYBR"' Green Master Mix (Applied Biosystems. Life Technologies, Carlsbad, CA, USA), and a relative sta ndard curve quantification method for used for analysis [27) . PCR conditions were used according to the manufacturer's instructions. ACTB m RNA was amplified as an internal control (GenBank accession No. NM 001101 ). Each amplification reaction was evaluated by using a me lting curve analysis. PCR products were visuali zed using agarose gel electrophoresis with ethidium bromide staining.
lmmunoblot analysis
Whole-celllysates were prepared as previously described [23) . Lysates (50 J.Lg) were subjected to immunoblot analysis using SOS-PAGE ( 12.5%), followed by electrotransfer onto nitrocellulose filters. The filte rs were incubated with primary antibodies, followed by peroxidase-conjugated lgG antibodies (MBL. Nagoya,japan). Anti-tubulin antibody was used to assess the levels of protein loaded pe r lane (Oncogene Research Products, Cambridge, MA. USA). The immune complex was visualized using an ECL Western-blot detection system (Amersham, Aylesbury, UK ). Antibody for CLDN1 (clone 2C1) was established by us [28) . Antibodies for epidermal growth factor receptor ( EGFR; Cell Signaling Technology, Beverly, MA. USA). phosphorylated EGFR (pTyr992, Cell SignalingTechnology). extracellular signal-regulated kinase 1/ 2 (ERK1/2; Santa-Cruz) and phosphorylated ERK1/2 (Santa-Cruz) m atrix metalloproteinase 9 (MMP9, Novocastra Laboratories. Newcastle upon Tyne. UK). CLDN2, 3, 5, 6. 7, 8, and 9 (rabbit polyclonal. Biorbyt, Cambridge, UK) were used as primary antibodies.
lmmunoprecipitation
For immunoprecipitation, the lysates were pre-cleaned in lysis buffer with protein A/G agarose (Santa-Cruz) for 1 hour at 4 'C and subsequently centrifuged. The supernatants were incubated w ith anti-CLDN4 antibody ( 403) or anti-CLDN 1 antibody (2C1) and protein A/G agarose for 16 hours at 4 ' C. Precipitates were collected by centrifugation and washed 5 times w it h lysis buffer for SOS-PAGE. The precipitants were detected by antibodies for CLDN4 ( 403), CLDN1 (2C1 ). CLDN3 and CLDN7 (Origene. Rockville, MD. USA). For loading control, 5 J.LL of each preimmunoprecipitated sample (lysate diluted with buffer) was slot-blotted onto nitrocellulose membrane and stained with Coomassie Blue.
Short interfering RNA
Flex iTube s hort interfering RNA (siR NA) for CLDN4 was purchased from SantaCruz. AIIStars Negative Control siRNA was used as a control (Qiagen). Cells were transfected with 50 nM si RNA using Lipofectamine 2000 (Invitrogen ), according to the manufacturer's instructions.
Intracellular platinum
T24 cells (1 x 10 10 ) were digested with proteinase K for 2 hat 45 'C, followed by treatment with 65% nitric acid overnight at 80 'C. The suspension was analyzed using a flame less atomic absorption spectrometer (MS) to measure the platinum concentration (A,= 265.9 nm). using an AAS platinum standard (S igma-Aidrich. St Louis. MO, USA).
In vitro penneability assay
To carry out multiple cell layer insert assays, T24 cells (1 x 104) were seeded on the bottom of uncoated insert wells (pore size. 3 J.Lffi; diameter, 5 mm; BD biosciences ). and the culture medium was changed to DMEM with 2% bovine serum albumin (BSA; Sigma-Aidrich). peroxidase-conjugated mouse lgG (lgG-PO; 0.5 J.Lg/mL; DAKO) was added to the insert chambers. After cells were treated with 4D3 antibody for 6 h, media from the inserts and lower chambers were collected into a 96-well ELISA plate, which was calor-developed with the addition of PO (0.5 J.Lg/mL) or TMB ( 10% vfv). The reaction was stopped by the addition of 2N H2S0 4. and the optical density at 450 mn ( OD450) was measured.
An lnVitro Vascular Permeability Kit (Trevigen Inc. Gaithersburg, MD) was used to determine permeation of fluorescein isothiocyanate (FITC)-dextran in a monolayer ofT24 or RT4 cells. according to the manufacturer's instruction. Cytochalasin B (1 J.Lg/mL) was used as a positive control [29) .
To carry out a multiple cell layer microcanier assay, I 0 mg of microcanier (Corning Inc., earning, NY, USA) was incubated with T24 cells (1 x 10 4 ). After48 h. microcarriers were collected by using filter paper and subsequent centrifugation at 5,000 x g. for 5 min. at 4 ' C. The supernatant was used for subsequent ELISA.
Enzyme-linked immunosorbent assay
ELISA kits were used to measure protein concentrations of epidermal growth factor (EGF) (R&D Systems Inc., Minneapolis, MN, USA ). and vascular endothelial growth factor (VEGF) (Abeam, Cambridge, UK ). accord ing to manufacturers' instructions.
Animal tumor models
To establish a subcutaneous turner model, T24 cancer cells (1 x 107) were inoculated into the scapular subcutaneous tissues of nude mice. For the lung metastasis model. T24 cancer cells (1 x 106) were inoculated into the caudal vein. Mice lungs were observed for 4 weeks following inoculation. The lungs were slices by 2 mmthicknes s and the metasta tic foci were counted unde r observation u sing a stereomicroscope (Nikon. Tokyo, japan). CDDP and/or 403 were administrated into the peritoneal cavity.
For the subcutaneous model, CDDP (3 mg/kg body weight. diluted with saline) and /or 403 ( 1 mg/kg body weight, diluted with saline) were injected into the perito neal cavity simultaneously on Days 1. 3, and 7. For the lung cancer mode l. COOP (3 mgfkg body weight) and/or 403 (1 mg/kg body weight) were injected into the peritoneal cavity simultaneously on Days 1, 8, 15, and 22. In both models. each group contained 5 mice. 
Antibody accumulation in the tumor
Statistical analysis
Statistical significance was calculated by using two-tailed Fisher's exact, Chisquare. and unpaired Mann-Whitney tests by using lnStat software (Graphpad, Los Angeles, CA, USA). Survival curves were calculated by using a Kaplan-Meier model (Statview 4.5, Abacus Concepts, Inc .. Berkeley, CA, USA). Differences in survival were calculated by using the Cox prop01tional hazard model (Statview 4.5). Statistical significance was defined as a two-sided p-value of< 0.05.
Results
Creation of an anti-11CLDN4 monoclonal antibody
We generated an anti-CLDN4 mAb ( 403) by genetic immunization using a full-length CLDN4 cONA expression vector. Analysis of antibody isotypes revealed that the 403 isotype was IgG2b. SPR analysis of 403 showed the following binding kinetics: ka value, 1.99 x 10 4 1/Ms; kd value, 8.27 x 10-4 1/s, and KO value, 41.5 nM. 403 bound to hCLDN4-expressing cells, but not to hCLDNl, 2, 3, 5, 6, 7, 9, or mCLDN4-expressing cells (Fig. lA) . To confirm the specificity of the 403 antibody, an immunoprecipitation was performed (Fig. 18 ) . Lysate of T24 cells were immunoprecipitated with 403 or anti-CLDN1 antibody (2C1 ). CLDN4 was detected by 403 in the 403-precipitant alone. CLDN4 knockdown abrogated CLDN4 precipitation. Moreover, CLDN1, 3, or 7 was not detected in 403-precipitants by their specific antibodies. Therefore, 403 is a specific mAb to hCLDN4.
We also examined the endogenous protein expression levels of hCLDNl. 2, 3, 4, 5, 6, 7, 8, and 9 in HT1080 cells, which were treated with control siRNA or CLDN4 siRNA (Fig. 1C) . The constitutive expression ofhCLDN4 was undetectable in HT1080 cells. HT1080 cells transfected with human CLDN4 gene (HT1080-hCLDN4 cells), were treated with control siRNA or CLON4 siRNA. CLON4 expression was disappeared in CLON4-knockdowned cells, whereas the expressions of hCLDNl, 2, 3, 5, 6, 7, 8, and 9 were not affected by CLDN4 knockdown.
Expression of CLDN4 in human bladder cancer detected by the 4D3 monoclonal antibody
403 detects the expression of CLDN4 by binding to its extracellular domain, in contrast to other available anti-CLON4 antibodies. CLON4 was detected at intercellular borders in non-cancerous urothelium and low-grade/non-invasive cancer ( Fig. 2A-B) , whereas it was overexpressed and located at the cytoplasmic membrane and in the cytoplasm in high-grade, invasive, and metastasizing cancers (Fig. 2C-O ) . In contrast, unimmunized rat IgG showed no signals (Fig. 2E) . Results from the examination of 86 bladder cancer tumors are shown in Table 1 . CLON4 expression was significantly associated w ith local invasion (pT, P = 0.0123), nodal metastasis (pN, P= 0.0059), distant metastasis (pM, P= 0.0341 ), and pathological stage (P= 0.0011 ), but not with histological grade. Especially, the two cases of pM1 showed metastasis to the bone and the lung. The mean staining index (strength x area) of CLDN4 in the two cases (275 ± 7) expressions were significantly higher than that in the pMO cases (146±69) (P=0.0101).
Effect of 4D3 on bladder cancer cells
The human bladder cancer cell lines, RT4 (low-grade cancer derived) and T24 (high-grade cancer derived) expressed CLDN4 mRNA and protein (Fig. 3A) . Cell growth and invasion of RT4 and T24 cells were modestly inhibited by 403 in a dose-dependent manner, w hereas apoptosis was increa sed by 4 03 in a do sedependent manner (Fig. 3B-O) .
Multicarrier assays showed that intracarrier EGF concentration was significantly reduced by 403 treatment (Fig. 3E) . Subsequent phosphorylation of EGFR and ERI<l/2 was also decreased by 403 treatment (Fig. 3F ). In the same assay, intracarrier VEGF concentration was significantly reduced by 403 treatment (Fig. 3G ) . 403-treated cells showed lower mRNA expression of VEGF and HJF-1 a, which suggests an improvement in hypoxic conditions (Fig. 3H ) .
Effects of 4D3 on in vitro bladder cancer cells conwrrently treated with cisplatin
COOP is the most common chemotherapeutic agent used in bladder cancer treatment, and we examined the effects of concurrent 403 and COOP treatment on bladder cancer cells (Fig. 4) . COOP caused growth inhibition ofT24 and RT4 cells in a dose-dependent manner. Treatment with 403 enhanced the inhibition of cell growth caused by COOP, in both cell lines (Fig. 4A-B) . Intracellular platinum concentration was significantly increased in cells treated with 403 compared to those without 403 treatment (Fig. 4C-O) .
Using a multiple cell layer permeability assay, peroxidaselabeled IgG were added to the upper chamber and permeated through the T24 cell layer into the lower chamber, in a 403 dosedependent manner (Fig. 4E) . In contrast, a control IgG did not affect the permeability. Using a monolayer permeability assay, FITCdextran was shielded by T24 or RT4 cell layers. 403 treatment inhibited shielding at the same levels as non-cell or cytochalasin B treatment (Fig. 4F) . (H) mRNA expression of VEGF and H/F-1 a (error bar, standard deviation calculated from three independent experime nts).
Effect of 403 on in vivo bladder cancer cells concurrently treated with dsplatin
We next examined the effect of concurrent 403 and COOP treatment on subcutaneous tumors in nude mice (Fig. SA) (1 !lg/mL). Cytochalasin B (CCB. 1!lg/mL) was used as a positive control [27] (error bar, standard deviation calculated from three independent experiments; ' P < 0.01, # P < 0.0001 ).
52% and 70%, respectively. In the lung metastasis model, treatment with 403, COOP, or COOP+403 decreased the number of lung metastasis by 29%, 50%, and 74%, respectively, at week 4 ( Fig. SB) . The localization of the administrated 403 was examined by detection of ICG-labeled 403 in whole mouse imaging (Fig. SC) and of FITC-labeled 403 in the tumor tissue by fluorescent microscopy in frozen section (Fig. 50) . 403 accumulation at the subcutaneous tumor was found by whole mouse imaging. 403 immunoreactivity was observed on the cell-cell boundary, which is compatible to the tight junction.
To confirm the enhancement of permeability of cancer tissue, FITC-dextran was administrated for subsequent detection in the tumors (Fig. SE-F) . FITC-dextran infiltrated the intracellular spaces more prominently in 403-treated mice than in lgG-treated control mice (Fig. SE) . The permeated areas were also significantly larger in 403-treated mice than that in IgG-treated control mice (Fig. SF) .
The effect of the treatment was examined by analyzing survival in mice (Fig. SF) . In the T24 subcutaneous tumor model, survival was significantly improved by COOP or COOP+403 treatment (Fig. SG ) . The survival rates at day 28 were 0%, 0%, 33% and 50% in the untreated mice, and 403, COOP, and COOP+403-treated mice, respectively. The mice treated with COOP+403 showed significantly improved survival than that in the untreated mice 
Discussion
CLDN is an essential protein in maintaining cell polarity and molecular trafficking, via tightjunctions.ln this study, we established an antibody to the extracellular domain of CLDN4, which is only the second antibody of this kind [31 ] . When CLDN expression is increased, the barrier function of cancerous epithelia changes, and it often displays a disorganized arrangement of tight junction strands, with increased permeability to paracellular markers [32] . Dysregulation of these functions contributes to initiation and progression of cancer [8] . Altered CLDN expression has been reported in many types of epithelial cancers in a stage-and tumor-specific manner [8, 32] , and the present study shows overexpression of CLDN4 in bladder cancer.
Our data demonstrates that the 403 anti-CLON4 antibody inhibited growth, invasion, and survival of cancer cells in the condition of in vitro or of the mouse tumor models. Considering that anti-CLDN4 antibody, 403 recognized the extracellular loops 1 and 2, binding of 403 to CLDN4 is thought to block homophilic transinteraction, which forms gap between 2 strands of tight junctions. The gap abrogates barrier-and fence-functions of tumor t issues [33, 34] . We then evaluated the loss of tight junctions in cancer tissue using two different methods. First, we examined the confinement ofEGF, a cancer-stimulating growth factor, by tight junctions by using microcarrier beads. Treatment with the 403 anti-CLDN4 antibody allowed leakage of EGF from the beads, which suppressed phosphorylation of EGFR and ERK1 /2 and also expression of MMP9. Thus the tumor growth and invasion might be inhibited by 403 treatment. In contrast, CLDN4 maintains the internal environment of the tumor, which induces HIF-1a and VEGF due to the hypoxic condition. CLDN4 thus affects the expression and secretion of these factors and also the signal pathway by an indirect manner.
Second, we examined the diffusion of anti-cancer molecules into the intercellular space treated with 403. Anti-CLDN4 antibody treatment increased permeability of multiple cell layers allowing permeation of COOP into tu m or tissue, and subsequent intracellular accumulation. These effects inhibit cancer cells and increase the efficacy of anti-cancer drugs. lt has been reported that an increase in vascular permeability leads to enhanced anti-cancer drug concentrations in tumor tissue [35] , but as CLDN4 is not involved in endothelial tight junctions [36] , we believe that the effect of the anti-CLDN4 antibody reflects the increased permeability of cancer cell tight junction. CLDN4 has also been reported to regulate sensitivity to COOP by controlling the expression of copper and the COOP influx transporter, CTR1 [37] , but these modes of CDDP regulation by CLDN4 have not been examined in this study.
In some types of malignancies, an intrinsic decrease in CLDN4 expression has been associated with cancer cell discohesion, invasion, and metastasis [38, 39] . Knockdown of CLDN4 was shown to reduce tight junction formation, transepithelial resistance, and the paracellular flux of dextran, which enhances migration and invasion in in vitro assays, and increases lung metastasis [38] . In contrast, our data did not detect any effects of inhibition of CLDN4 by 403 in cancer cells with a metastatic phenotype. We also found that advanced cases of bladder cancer expressed CLDN4 at higher levels than early cases, suggesting that CLDN4 overexpression may be associated with tumor progression in bladder cancer, a different role than that associated with ovarian and colorectal cancer [38, 39] . Our data suggest that the role of CLDN4 in sustaining the internal microenvironment of the tumor might be advantageous for bladder cancer. Increased CLDN4 expression is epigenetically regulated by hypomethylation of CLDN4 in gastric cancer [ 40 ] . In contrast, during ovarian tumorigenesis, derepression of CLDN4 expression correlates with loss oftrimethylated histone H3 lysine 27 and H4lysine 20, in addition to DNA hypermethylation [41] .
CLDN4 is a widely distributed molecule in various epithelial tissues. Then toxicity by the targeting of CLDN4 is an essential issue. Because 403 antibody recognizes only human CLDN4 but not CLDN4 of rodent or other animals, evaluation of the toxicity using animals is not relevant. In literature, CLDN4 knockout mouse was reported [42] . The CLDN4-knockout mice show urothelial hyperplasia and lethal hydronephrosis; however, hetero-deficient mice do not show above anomaly. From the results, in the normal tissues, CLDN4 deficiency might result none or traceable dysfunction of tight junction.
Clostlidium perfringens toxin binds to both CLDN4 and CLDN3, and it provides pore formation in the plasma membrane [43] , which are causes of the strong cytotoxicity. For confirmation of safety of the antibody, evaluation by using primate models is thought to be good for preclinical examination.
Therapeutic targeting of CLDN4 has increasingly been proposed in the literature [44] [45] [46] . Several reports have recommended the use of bacterial toxins, such as C. perfringens enterotoxin (CPE) and the (-terminal domain ofCPE (C-CPE) as CLDN4 binders [44, 45] . lt has also been demonstrated that CLDN4 targeting is effective for treatment of cancer metastasis, by using C-CPE fused to a protein synthesis inhibitory factor [ 46] . We have also established bispecific antibodies to CLDN3 and 4, which show anti-tumor activity in in vivo and in vitro experiments [47] . The anti-tumor activity of the newly established 403 anti-CLDN4 antibody that we have demonstrated in this study, suggests that it might be effective in CLDN4-targeting therapy, alone and in combination with chemotherapy.
